Morning Market Gainers

Giga-tronics, Incorporated GIGA shares jumped 160.36 percent to $2.89 following the announcement of a software licensing agreement with Lockheed Martin Corporation LMT. Spherix Inc SPEX gained 25.43 percent to $0.439 as the company said it no longer has a $5 million payment due on Series I stock. TerraForm Power Inc TERP shares gained 19.57 percent to $8.25. Terraform Global is pulling out of deal to acquire shares of Renovia Energia, according to Reuters. David Tepper's Appaloosa issued a letter to TerraForm Power Directors. Analysts at Oppenheimer upgraded TerraForm Power from Perform to Outperform. Infoblox Inc BLOX shares rose 19.55 percent to $17.98 after the company reported better-than-expected results for its fiscal first quarter and issued a strong outlook. The company's board also announced a $100 million share buyback program. HF Financial Corp. HFFC shares climbed 18.18 percent to $19.18 after Great Western Bancorp Inc GWB announced plans to acquire HF Financial Corp in a transaction valued at $19.70 per share. XOMA Corp XOMA shares rose 13.91 percent to $1.51 after the company reported a license agreement with Novo Nordisk for XMetA program in diabetes. Abengoa SA (ADR) ABGB shares surged 14.08 percent to $2.35 after jumping 19.08 percent on Monday. Rayonier Advanced Materials Inc RYAM rose 11.86 percent to $12.54 after the company reported a new contract with Eastman Chemical through 2019 Mattress Firm Holding Corp MFRM shares gained 9 percent to $53.80. Mattress Firm agreed to acquire HMK Mattress Holdings LLC, the holding company of Sleepy's and related entities, for $780 million. The company reported preliminary Q3 adjusted earnings of $0.80 to $0.82 per share, and sales growth of 50.7 percent. Arena Pharmaceuticals, Inc. ARNA shares gained 8.79 percent to $2.60 after surging 11.16 percent on Monday. Eisai and Arena Pharmaceuticals reported the completion of enrollment in BELVIQ® (lorcaserin HCI) CAMELLIA-TIMI 61 study. Synthetic Biologics Inc SYN rose 3.15 percent to $2.95 after announcing positive topline results from first Phase 2A clinical trial of SYN-004 for the prevention of C. difficile infection.